PBAXU — Phoenix Biotech Acquisition Balance Sheet
0.000.00%
- $68.56m
- $69.84m
- 21
- 48
- 51
- 34
Annual balance sheet for Phoenix Biotech Acquisition, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | |
---|---|---|
Period Length: | — | — |
Source: | 10-K | 10-K |
Standards: | USG | USG |
Status: | Final | Final |
Cash | ||
Cash and Short Term Investments | 1.1 | 0.476 |
Prepaid Expenses | ||
Total Other Current Assets | ||
Total Current Assets | 1.36 | 42.4 |
Long Term Investments | ||
Other Long Term Assets | ||
Total Assets | 180 | 42.4 |
Payable / Accrued | ||
Accrued Expenses | ||
Notes Payable / Short Term Debt | ||
Total Other Current Liabilities | ||
Total Current Liabilities | 0.098 | 30.7 |
Total Long Term Debt | ||
Total Debt | ||
Total Other Liabilities | ||
Total Liabilities | 9.25 | 39.9 |
Non Redeemable Preferred Stock | ||
Common Stock | ||
Additional Paid In Capital | ||
Retained Earnings (Accumulated Deficit) | ||
Total Equity | 171 | 2.47 |
Total Liabilities & Shareholders' Equity | 180 | 42.4 |
Total Common Shares Outstanding |